Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Sire

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2018
PET-based prognostic survival model after radiotherapy for head and neck cancerJoël Castelli, A Depeursinge, A Devillers, et al.
ESMO Open|April 10, 2026
Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNEJ Fayette, C Cropet, C Toullec, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|June 12, 2024
[Informed consent in radiotherapy care]C Sire, A Ducteil, J-L Lagrange, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trialY Tao, J Biau, X S Sun, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2018
PET-based prognostic survival model after radiotherapy for head and neck cancerJoël Castelli, A Depeursinge, A Devillers, et al.
ESMO Open|April 10, 2026
Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNEJ Fayette, C Cropet, C Toullec, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|June 12, 2024
[Informed consent in radiotherapy care]C Sire, A Ducteil, J-L Lagrange, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trialY Tao, J Biau, X S Sun, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Pageof 3